A practical reference on Freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
| Property | Value | Notes |
|---|---|---|
| Purity specification (research grade) | Greater than 95 percent by HPLC | Area percent at 220 nm; method dependent |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical |
| Residual water | Reported by Karl Fischer titration | Affects peptide content calculation |
| Common synonyms | GLP-1 analog; GLP-1 receptor agonist peptide | Naming varies across catalogs |
| Container material | Low-binding polypropylene | Reduces adsorption at low concentration |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
== History == Congebec was founded in 1974 by Laurier Pedneault following the acquisition of a warehouse on Dalhousie street, near Quebec City's old port. In 1997 Congebec purchased its first warehouse in the Montreal region. In 2002, it was the first phase of construction for the Boucherville warehouse which was the beginning of a strong expansion for Congebec. In 2004, Congebec purchased the Centre Frigorifique Montérégie, which is now referred to as Sainte-Julie warehouse. In doing so, Congebec also purchased CFM logistics that now is Congebec's transport division. After the acquisition, Congebec became the largest refrigerated warehouse company in Quebec and second largest in Canada. In 2006, the Boucherville warehouse was considerably expanded. A seventh warehouse was built in Manseau in autumn 2008. This warehouse is almost entirely dedicated to the cranberry industry. In 2011, Congebec entered the Toronto market with the opening of an 8th refrigerated warehouse strategically located near Pearson Airport, with more than three million cubic feet. In 2013, Congebec conducted its largest expansion in history by acquiring four Westco Multitemp warehouses located in Calgary, Saskatoon and Winnipeg, which gave Congebec a total of more than 48.3 million cubic feet. In 2015, Capital régional et coopératif Desjardins (CRCD), a retail fund managed by Canadian private equity firm Desjardins Capital de risque, led an undisclosed investment in Congebec Logistic Inc.
== External links == P. Romano, C. Fiore, M. Paraggio, M. Caruso, A. Capece "Function of yeast species and strains in wine flavour". Archived 2015-06-06 at the Wayback Machine. International Journal of Food Microbiology 86 (2003). pp. 169–180.
The enzyme is named for the reaction in the direction from the nucleotide to quinolinic acid but in the mammalian liver only proceeds in the direction shown, with carbon dioxide and pyrophosphate (PPi) as byproducts. This reaction is part of the biosythesis pathway to the coenzyme, nicotinamide adenine dinucleotide, in both plants and animals. This enzyme is a glycosyltransferase, specifically a pentosyltransferase. The systematic name of this enzyme class is nicotinate-nucleotide:diphosphate phospho-alpha-D-ribosyltransferase (carboxylating). Other names in common use include quinolinate phosphoribosyltransferase (decarboxylating), quinolinic acid phosphoribosyltransferase, QAPRTase, NAD+ pyrophosphorylase, nicotinate mononucleotide pyrophosphorylase (carboxylating), and quinolinic phosphoribosyltransferase.
Seeing her escape avenue, Owens agreed and vacuumed the house to indicate her acquiescence to becoming an extended member of the family. Later that day, Owens escaped from a launderette she and Rose had entered and returned home. Although initially too ashamed to divulge what had happened, when her mother noted the welts, bruises and exposed subcutaneous tissues on her daughter's body, Owens burst into tears and confided her ordeal. Owens' mother immediately reported her daughter's story to police, and the Wests were arrested and charged with assault, indecent assault, actual bodily harm and rape. The case was tried at Gloucester Magistrates Court on 12 January 1973, but by this date Owens had decided she could not face the ordeal of giving testimony. All charges pertaining to her ordeal were dropped, and the Wests agreed to plead guilty to the reduced charges of indecent assault and causing actual bodily harm. Rose and Fred were each fined £50 (equivalent to £1,000 in 2025) and the couple were allowed to walk free. When Owens heard this news, she attempted suicide.
Sources: en.wikipedia.org
=== 2012—2017: ZeniMax Media subsidiaries === Antonov also worked on Dishonored's DLC. Following this, Antonov became the visual design director for American company ZeniMax Media, meaning he worked on projects developed by ZeniMax's subsidiary developers—including Bethesda Game Studios, MachineGames, id Software, and Arkane—and made sure "the level of visual design and fiction" coming out of them was "the highest possible", Robert Purchese wrote. In 2012, a ZeniMax subsidiary named BattleCry Studios was founded in Austin, Texas, by developer Rich Vogel. Antonov worked on their planned debut release, a team-based multiplayer FPS titled BattleCry. In 2015, Bethesda Softworks, the planned publisher of BattleCry, revealed their "concerns" about the viability of the game releasing, and it was cancelled in 2017. Antonov was the additional art director of MachineGames' Wolfenstein: The New Order (2014); a visual designer of Dire Wolf Digital's The Elder Scrolls: Legends (2017); and a consultant on Bethesda Game Studios' Fallout 4 (2015), id Software's Doom (2016), and Arkane's Dishonored 2 (2016) and Prey (2017).
=== 6.5% salt broth === The 6.5% salt broth test is used to analyze the tolerance level of various bacteria under halophilic conditions. This test is used because most organisms cannot survive in high salt concentrations while Staphylococci, Enterococci, and Aerococci are all expected to tolerate 6.5% NaCl concentrations.
Excitatory amino acid transporter 1 (EAAT1) is a protein that, in humans, is encoded by the SLC1A3 gene. EAAT1 is also often called the GLutamate ASpartate Transporter 1 (GLAST-1). EAAT1 is predominantly expressed in the plasma membrane, allowing it to remove glutamate from the extracellular space. It has also been localized in the inner mitochondrial membrane as part of the malate-aspartate shuttle.
Recent estimates have found ~135,000 validated nonsynonymous cSNPs currently housed within SwissProt. In dbSNP, there are 4.7 million candidate cSNPs, yet only ~670,000 cSNPs have been validated in the 1,000-genomes set as nonsynonymous cSNPs that change the identity of an amino acid in a protein. Dark proteome. The term dark proteome coined by Perdigão and colleagues, defines regions of proteins that have no detectable sequence homology to other proteins of known three-dimensional structure and therefore cannot be modeled by homology. For 546,000 Swiss-Prot proteins, 44–54% of the proteome in eukaryotes and viruses was found to be "dark", compared with only ~14% in archaea and bacteria. Human proteome. Currently, several projects aim to map the human proteome, including the Human Proteome Map Archived 2020-08-06 at the Wayback Machine, ProteomicsDB, isoform.io, and The Human Proteome Project (HPP). Much like the Human Genome Project, these projects seek to find and collect evidence for all predicted protein coding genes in the human genome. The Human Proteome Map currently (October 2020) claims 17,294 proteins and ProteomicsDB 15,479, using different criteria. On October 16, 2020, the HPP published a high-stringency blueprint covering more than 90% of the predicted protein coding genes. Proteins are identified from a wide range of fetal and adult tissues and cell types, including hematopoietic cells.
=== Selected publications === Ariely, Dan; Loewenstein, George; Prelec, Drazen (2003), "Coherent Arbitrariness: Stable demand curves without stable preferences", The Quarterly Journal of Economics, 118 (1): 73–106, doi:10.1162/00335530360535153, archived from the original on April 4, 2012 Ariely, Dan (2000), "Controlling information flow: Effects on consumers' decision making and preference", Journal of Consumer Research, 27 (2): 233–248, CiteSeerX 10.1.1.203.1798, doi:10.1086/314322 {{citation}}: Cite uses deprecated parameter |citeseerx= (help) Ariely, Dan; Wertenbroch, Klaus (2002), "Procrastination, Deadlines, and Performance: Self-Control by Precommitment" (PDF), Psychological Science, 13 (3): 219–224, doi:10.1111/1467-9280.00441, PMID 12009041, S2CID 3025329 Heyman, James; Ariely, Dan (2004), "Effort for Payment: A Tale of Two markets" (PDF), Psychological Science, 15 (11): 787–793(7), doi:10.1111/j.0956-7976.2004.00757.x, PMID 15482452, S2CID 8573184 Carmon, Ziv; Ariely, Dan (2000), "Focusing on the Forgone: Why Value can Appear so Different to Buyers and Sellers" (PDF), Journal of Consumer Research, 27 (3): 360–370, doi:10.1086/317590 Shiv, Baba; Carmon, Ziv; Ariely, Dan (2005), "Placebo Effects of Marketing Actions: Consumers May Get What They Pay For" (PDF), Journal of Marketing Research, XXII (4): 383–393, doi:10.1509/jmkr.2005.42.4.383, S2CID 14170707 Mazar, Nina; Ariely, Dan (2006), "Dishonesty in Everyday Life and Its Policy Implications" (PDF), Journal of Public Policy & Marketing, 25 (1): 117–126, doi:10.1509/jppm.25.1.117, S2CID 2813683 Lee, Leonard; Frederick, Shane; Ariely, Dan (2006), "Try it, you'll like it: The influence of expectation, consumption, and revelation on preferences for beer" (PDF), Psychological Science, 17 (12): 1054–1058, doi:10.1111/j.1467-9280.2006.01829.x, PMID 17201787, S2CID 1252769 Ariely, Dan; Gregory S. Berns (March 3, 2010). "Neuromarketing: the hope and hype of neuroimaging in business" (PDF). Nature Reviews Neuroscience. 11 (4): 284–292. doi:10.1038/nrn2795. PMC 2875927. PMID 20197790. Archived from the original (PDF) on July 11, 2013. Ariely, Dan; Michael I. Norton; Daniel Mochon (July 2012). "The IKEA effect: When labor leads to love" (PDF). Journal of Consumer Psychology. 3. 22 (3): 453–460. doi:10.1016/j.jcps.2011.08.002. Archived from the original (PDF) on May 20, 2014.
Sources: en.wikipedia.org
=== Impaired glucose tolerance === Impaired glucose tolerance (IGT) is diagnosed with an oral glucose tolerance test. According to the criteria of the World Health Organization and the American Diabetes Association, impaired glucose tolerance is defined as:
===== Antimicrobial pesticide safety ===== Antimicrobial pesticides have the potential to be a major factor in drug resistance. Organizations such as the World Health Organization call for significant reduction in their use globally to combat this. According to a 2010 Centers for Disease Control and Prevention report, health-care workers can take steps to improve their safety measures against antimicrobial pesticide exposure. Workers are advised to minimize exposure to these agents by wearing personal protective equipment such as gloves and safety glasses. Additionally, it is important to follow the handling instructions properly, as that is how the EPA has deemed them as safe to use. Employees should be educated about the health hazards and encouraged to seek medical care if exposure occurs.
Gepotidacin, sold under the brand name Blujepa, is an antibiotic medication used for the treatment of urinary tract infection or uncomplicated urogenital gonorrhea. Gepotidacin is a triazaacenaphthylene bacterial type II topoisomerase inhibitor. It is used as the salt gepotidacin mesylate, and is taken by mouth. Gepotidacin was approved for medical use in the United States in March 2025. The US Food and Drug Administration considers it to be a first-in-class medication. It is the first triazaacenaphthylene antibiotic to be approved in the US.
== Types == The glomerular basement membrane of the kidney, is an unusually thick basement membrane. It serves as part of a molecular filter that prevents macromolecules from the blood from entering the urine. It is faced by a cell layer on either side, the endothelium, and the podocytes, and has a thicker structure of three laminae. It is thicker by the fusion of the basal lamina from the endothelium of glomerular capillaries and the podocyte basal lamina. These layers are known as the central lamina densa, and on each side, a lamina rara – a lamina rara interna facing the endothelium, and a lamina rara externa facing the podocytes. In the lung the basement membrane of the alveolus and that of the surrounding capillary are fused, allowing an easy exchange of gases. In the mucosae the basement membrane lies between one or more layers of epithelial cells that it supports, and the underlying attached loose connective tissue called the lamina propria.
Sources: en.wikipedia.org
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.
Each cycle exposes the peptide to ice-liquid interfaces where unfolding and aggregation can occur. Aggregates may not redissolve and can alter measured activity. Aliquoting before the first freeze reduces the number of cycles any single portion experiences.
It usually reports purity by HPLC, identity by mass spectrometry, peptide content, appearance, and residual moisture or counterion content. The analytical method behind each value should be stated. Acceptance criteria are set by the supplier or the buyer's specification.
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.